| Branch Banking and Trust Co.
 
 From: Vaughn, Mark [mailto:MVaughn@BBandT.com]
 Sent: Friday, May 28, 2004 3:22 PM
 To: Comments
 Subject: RIN 3064-AC81
 Mr. Robert E. Feldman, Executive SecretaryAttn: Comments
 Federal Deposit Insurance Corporation
 550 17th Street, NW
 Washington, DC 20429
 RE: 12 CFR Part 334 - RIN 3064-AC81 BB&T Corporation ("BB&T") appreciates the opportunity to comment on thejoint agencies' proposed rulemaking regarding medical privacy. BB&T is a
 regional financial holding company with numerous banks and non-bank
 subsidiaries. Our comments are as follows:
 We think the overall regulation prescribed by the joint agencies' isappropriate to protect financial institutions needs with respect to the use
 of medical information in the credit granting process.
 We think the existence of medical information in a credit file, in itself,does not constitute a violation of section 604(g)(2). Section 411(a) amends
 the Fair Credit Reporting Act by adding new section 604(g)(2) to prohibit
 creditors from obtaining or using medical information pertaining to a
 consumer in connection with any determination of the consumer's eligibility,
 or continued eligibility, for credit. We do not agree that Congress
 intended Section 604(g)(2) to "contain two independent prohibitions - a
 prohibition on obtaining medical information and a prohibition on using
 medical information" as interpreted by the joint agencies' and as written in
 the proposals' Background Supplementary Information. In fact, we think the
 intent was to follow the precedent set by the use of governmental monitoring
 information (ethnicity, race & sex) under the Equal Credit Opportunity Act.
 The intent was to prohibit any creditor from discriminating against any
 applicant, with respect to any aspect of a credit transaction on the basis
 of prohibited factors. Equal Credit Opportunity Act not only allows
 creditors to obtain governmental monitoring information in the credit file
 but also requires us to obtain and use this information in certain cases.
 We do not think the intent was to consider these as two independent
 prohibitions but an overall attempt at prohibiting creditors from
 discriminating against any applicant based on medical information.
 The existence of medical information in a credit file does not in itselfshow that a creditor has obtained and used this information in connection
 with any determination of a consumer's eligibility for credit. This will put
 an unintentional burden on financial institutions to justify if the obtained
 medical information meets one of the exceptions even though it was not
 actually used in connection with any credit determination. We think the
 focus will be on the information being obtained and not on if it has been
 used in connection with determination of the consumer's eligibility. We
 feel the current proposal will put too much emphasis on the existence of
 medical information and less on how or if this information was used.
 It is also true that the mere existence of medical information in a creditfile would put burden on financial institutions to show written proof that
 it was either solicited by the creditor or provided unsolicited by the
 applicant. Based on the proposal examples regardless if solicited or
 unsolicited the creditor should not make a credit decision based on the
 applicant's medical condition. This is true even if the medical information
 was obtained in a credit file or verbally received from the consumer. Again
 the burden of proof as to if medical information was used as part of the
 credit determination or if it was solicited or unsolicited by the applicant
 should not be the unintentional result of this proposal. Did the creditor
 discriminate against any applicant based on medical information?
 The joint agencies' should amend their regulation to state that theexistence of medical information in the credit file, in itself, does not
 constitute a violation of section 604(g)(2). A creditor may obtain and use
 medical information pertaining to a consumer in connection with any
 determination of the consumer's eligibility, or continued eligibility, for
 credit as long as the examples of acceptable practices are followed.
 The joint agencies' have done a great job at explaining when it isacceptable to obtain and use medical information. We agree certain
 acceptable practices need to be followed. Thank you for the opportunity to
 provide these comments. We understand the difficulty of prescribing a
 regulation that is necessary and appropriate to protect legitimate business
 needs with respect to the use of medical information in the credit granting
 process. We commend you for trying to write a regulation that benefits all.
 Very truly yours, Mark D. VaughnBranch Banking and Trust Co.
 Vice President and
 Corporate Compliance Officer, CRCM
 Phone: 252-246-4347
 Fax: 252-246-4895
 Email: mvaughn@bbandt.com
 
   |